Chemical Radiosensitizers for Use in Radiotherapy

Clinical Oncology

Volumn 19, Issue 6, 2007, Pages 397-417

  Wardman, P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chemoradiation; DNA; hypoxia; nitroimidazoles; oxygen; radiosensitizers

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; AG 14361; ALKYLATING AGENT; ANTHRAQUINONE; CAMPTOTHECIN; CARBOGEN; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; DNA; DNA TOPOISOMERASE INHIBITOR; FLUOROPYRIMIDINE; FREE RADICAL; GADOLINIUM CHELATE; GEFITINIB; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMORAZOLE; NITRIC OXIDE; NITROIMIDAZOLE; OXIDOREDUCTASE; OXYGEN; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; RAS PROTEIN; TEMOZOLOMIDE; TIRAPAZAMINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANEMIA; APOPTOSIS; ARTICLE; BINDING AFFINITY; BLADDER CANCER; CANCER RADIOTHERAPY; CELL HYPOXIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG BINDING; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG STRUCTURE; DRUG TARGETING; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; CELL COMMUNICATION; CELL HYPOXIA; CYTOTOXINS; DNA REPAIR; DNA, NEOPLASM; FREE RADICAL SCAVENGERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 34347240794     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.03.010     Document Type: Article

References (260)

1. Steel G.G. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 5 (1979) 1145-1150
2. Steel G.G. Basic clinical radiobiology (1997), Arnold, London
3. Wilson G.D., Bentzen S.M., and Harari P.M. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16 (2006) 2-9
4. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm - general principles. Nat Clin Pract Oncol 4 (2007) 86-100
5. Tannock I.F. Treatment of cancer with radiation and drugs. J Clin Oncol 14 (1996) 3156-3174
6. Poggi M.M., Coleman C.N., and Mitchell J.B. Sensitizers and protectors of radiation and chemotherapy. Curr Probl Cancer 25 (2001) 331-411
7. Spalding A.C., and Lawrence T.S. New and emerging radiosensitizers and protectors. Cancer Invest 24 (2006) 444-456
8. Horsman M.R., Bohm L., Margison G.P., et al. Tumor radiosensitizers - current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys 64 (2006) 551-561
9. Coleman C.N., and Turrisi A.T. Radiation and chemotherapy sensitizers and protectors. Crit Rev Oncol Hematol 10 (1990) 225-252
10. Grdina D.J., Murley J.S., and Kataoka Y. Radioprotectants: current status and new directions. Oncology 63 Suppl. 2 (2002) 2-10
11. Weiss J.F., and Landauer M.R. Radioprotection by antioxidants. Ann NY Acad Sci 899 (2000) 44-60
12. Thomas C.T., Ammar A., Farrell J.J., and Elsaleh H. Radiation modifiers: treatment overview and future investigations. Hematol Oncol Clin North Am 20 (2006) 119-139
13. Shenoy M.A., Asquith J.C., Adams G.E., Michael B.D., and Watts M.E. Time-resolved oxygen effects in irradiated bacteria and mammalian cells: a rapid-mix study. Radiat Res 62 (1975) 498-512
14. Michael B.D., Harrop H.A., and Maughan R.L. Fast response methods in the radiation chemistry of lethal damage in intact cells. In: Okada S., Imamura M., Terashima T., and Yamaguchi H. (Eds). Radiation research (Proceedings of the Sixth International Congress), Tokyo, Japanese Association of Radiation Research (1979) 288-296
15. Adams G.E. Chemical radiosensitization of hypoxic cells. Br Med Bull 29 (1973) 48-53
16. Fowler J.F., Adams G.E., and Denekamp J. Radiosensitization of hypoxic cells in solid tumours. Cancer Treat Rev 3 (1976) 227-256
17. Hall E.J. Radiobiology for the radiologist (2000), Lippincott Williams & Wilkins, Philadelphia
18. Denny W.A., Wilson W.R., and Hay M.P. Recent developments in the design of bioreductive drugs. Br J Cancer 74 Suppl. XXVII (1996) S32-S38
19. Naylor M.A., and Thomson P. Recent advances in bioreductive drug targeting. Mini Rev Med Chem 1 (2001) 17-29
20. Jaffar M., Abou-Zeid N., Bai L., et al. Quinone bioreductive prodrugs as delivery agents. Curr Drug Deliv 1 (2004) 345-350
21. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8 (2001) 739-761
22. Thomson P., Naylor M.A., Everett S.A., et al. Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4. Mol Cancer Ther 5 (2006) 2886-2894
23. Cohen-Jonathon E., Bernhard E.J., and McKenna W.G. How does radiation kill cells?. Curr Opin Chem Biol 3 (1999) 77-83
24. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
25. Janssen H.L., Haustermans K.M., Balm A.J., and Begg A.C. Hypoxia in head and neck cancer: how much, how important?. Head Neck 27 (2005) 622-638
26. Isa A.Y., Ward T.H., West C.M.L., Slevin N.J., and Homer J.J. Hypoxia in head and neck cancer. Br J Radiol 79 (2006) 791-798
27. Dendy P.P., and Wardman P. Hypoxia in biology and medicine - the legacy of L H Gray. Br J Radiol 79 (2006) 545-549
28. Whillans D.W., and Rauth A.M. An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res 84 (1980) 97-114
29. Koch C.J. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat Res 97 (1984) 434-442
30. Joiner M.C., Marples B., Lambin P., Short S.C., and Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 49 (2001) 379-389
31. Krause M., Wohlfarth J., Georgi B., et al. Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 81 (2005) 751-758
32. Palcic B., Brosing J.W., and Skarsgard L.D. Survival measurements at low doses: oxygen enhancement ratio. Br J Cancer 46 (1982) 980-984
33. Watts M.E., Hodgkiss R.J., Jones N.R., and Fowler J.F. Radiosensitization of Chinese hamster cells by oxygen and misonidazole at low X-ray doses. Int J Radiat Biol 50 (1986) 1009-1021
34. Marples B., Joiner M.C., and Skov K.A. The effect of oxygen on low-dose hypersensitivity and increased radioresistance in Chinese hamster V79-379A cells. Radiat Res 138 (1994) S17-S20
35. Wardman P., Rothkamm K., Folkes L.K., Woodcock M., and Johnston P.J. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 167 (2007) 475-484
36. Saunders M., and Dische S. Clinical results of hypoxic cell radiosensitization from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 74 Suppl. XXVII (1996) S271-S278
37. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
38. Feldmeier J.J. Hyperbaric oxygen for delayed radiation injuries. Undersea Hyperb Med 31 (2004) 133-145
39. Koch C.J., Oprysko P.R., Shuman A.L., Jenkins W.T., Brandt G., and Evans S.M. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res 62 (2002) 3626-3629
40. Chang T.M.S. Evolution of artificial cells using nanobiotechnology of hemoglobin based RBC blood substitute as an example. Artif Cells Blood Substit Immobil Biotechnol 34 (2006) 551-556
41. Harrison L., and Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 9 Suppl. 5 (2004) 31-40
42. Varlotto J., and Stevenson M.A. Anemia, tumor hypoxia, and the cancer patient. Int J Radiat Oncol Biol Phys 63 (2005) 25-36
43. Harrison L.B., Chadha M., Hill R.J., Hu K., and Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7 (2007) 492-508
44. Hirst D.G. What is the importance of anaemia in radiotherapy? The value of animal studies. Radiother Oncol 20 Suppl. 1 (1991) 29-33
45. Thomas G.M. Raising hemoglobin: an opportunity for increasing survival?. Oncology 63 Suppl. 2 (2002) 19-28
46. Rowinsky E.K. Novel radiation sensitizers targeting tissue hypoxia. Oncology 13 Suppl. 5 (1999) 61-70
47. Kaanders J.H.A.M., Bussink J., and van der Kogel A.J. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 14 (2004) 233-240
48. Aapro M., and Vaupel P. Erythropoietin: effects on life expectancy in patients with cancer-related anaemia. Curr Med Res Opin 22 Suppl. 4 (2006) 5-13
49. Calais G., and Hirst D.G. In situ tumour radiosensitization induced by clofibrate administration: single dose and fractionated studies. Radiother Oncol 22 (1991) 99-103
50. Abraham D.J., Wireko F.C., Randad R.S., et al. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 31 (1992) 9141-9149
51. Khandelwal S.R., Kavanagh B.D., Lin P.-S., et al. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice. Br J Cancer 79 (1999) 814-820
52. Wahr J.A., Gerber M., Venitz J., and Baliga N. Allosteric modification of oxygen delivery by hemoglobin. Anesth Analg 92 (2001) 615-620
53. Mehta M.P., and Suh J.H. Novel radiosensitizers for tumors of the central nervous system. Curr Opin Investig Drugs 5 (2004) 1284-1291
54. Rosenberg A., and Knox S. Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys 64 (2006) 343-354
55. Stea B., Suh J.H., Boyd A.P., Cagnoni P.J., Shaw E., and Group R.S. Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys 64 (2006) 1023-1030
56. Collingridge D.R., and Rockwell S. Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int J Cancer 90 (2000) 256-264
57. Nieder C., Zimmermann F.B., Adam M., and Molls M. The role of pentoxifylline as a modifier of radiation therapy. Cancer Treat Rev 31 (2005) 448-455
58. Kjellen E., Joiner M.C., Collier J.M., Johns H., and Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol 22 (1991) 81-91
59. Horsman M.R. Nicotinamide and the hypoxia problem. Radiother Oncol 22 (1991) 79-80
60. Rojas A., Denekamp J., Johns H., et al. Nicotinamide as a repair inhibitor in vivo: studies using single and fractionated X-ray doses in mouse skin and kidneys. Radiat Res 145 (1996) 419-431
61. Rojas A., Vojnovic B., Johns H., et al. Radiosensitization in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated X-ray schedules. Radiother Oncol 39 (1996) 53-64
62. Hoskin P.J., and Saunders M.I. ARCON. Clin Oncol (R Coll Radiol) 6 (1994) 281-282
63. Saunders M.I., Hoskin P.J., Pigott K., et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol 45 (1997) 159-166
64. Hoskin P.J., Saunders M.I., Phillips H., et al. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer 76 (1997) 260-263
65. Kaanders J.H.A.M., Stratford M.R.L., Liefers J., et al. Administration of nicotinamide during a five to seven week course of radiotherapy: pharmcokinetics, tolerance, and compliance. Radiother Oncol 43 (1997) 67-73
66. Hoskin P.J., Rojas A.M., Phillips H., and Saunders M.I. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 103 (2005) 2287-2297
67. Kaanders J.H.A.M., Bussink J., and van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3 (2002) 728-737
68. Bernier J., Denekamp J., Rojas A., et al. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiother Oncol 55 (2000) 111-119
69. Hoogsteen I.J., Pop L.A.M., Marres H.A.M., et al. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 64 (2006) 83-89
70. Adams G.E., and Cooke M.S. Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol 15 (1969) 457-471
71. Adams G.E., Asquith J.C., Dewey D.L., Foster J.L., Michael B.D., and Willson R.L. Electron affinic sensitization. Part II: para-nitroacetophenone: a radiosensitizer for anoxic bacterial and mammalian cells. Int J Radiat Biol 19 (1971) 575-585
72. Chapman J.D., Webb R.G., and Borsa J. Radiosensitization of mammalian cells by p-nitroacetophenone. I. Characterization in asynchronous and synchronous populations. Int J Radiat Biol 19 (1971) 561-573
73. Asquith J.C., Foster J.L., Willson R.L., Ings R., and McFadzean J.A. Metronidazole ('Flagyl'). A radiosensitizer of hypoxic cells. Br J Radiol 47 (1974) 474-481
74. Adams G.E. Hypoxia-mediated drugs for radiation and chemotherapy. Cancer 48 (1981) 696-707
75. Stewart F.A., Denekamp J., and Randhawa V.S. Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br J Cancer 45 (1982) 869-877
76. Hendry J.H. Sensitization of hypoxic normal tissue. Br J Cancer 37 Suppl. III (1978) 232-234
77. Fowler J.F. Chemical modifiers of radiosensitivity - theory and reality: a review. Int J Radiat Oncol Biol Phys 11 (1985) 665-674
78. Wouters B.G., and Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147 (1997) 541-550
79. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6 (1994) 509-518
80. Adams G.E., Clarke E.D., Flockhart I.R., et al. Structure-activity relationships in the development of hypoxic cell radiosensitizers: I. Sensitization efficiency. Int J Radiat Biol 35 (1979) 133-150
81. Adams G.E., Clarke E.D., Gray P., et al. Structure-activity relationships in the development of hypoxic cell radiosensitizers: II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol 35 (1979) 151-160
82. Coleman C.N., Wasserman T.H., Urtasun R.C., et al. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. Int J Radiat Oncol Biol Phys 18 (1990) 389-393
83. Smithen C.E., Clarke E.D., Dale J.A., et al. Novel (nitro-1-imidazolyl) alkanolamines as potential radiosensitizers with improved therapeutic properties. In: Brady L.W. (Ed). Radiation sensitizers: their use in the clinical management of cancer (1980), Masson, New York 22-32
84. Dennis M.F., Stratford M.R.L., Wardman P., and Watts M.E. Cellular uptake of misonidazole and analogues with acidic or basic functions. Int J Radiat Biol 47 (1985) 629-643
85. Watts M.E., Dennis M.F., and Roberts I.J. Radiosensitization by misonidazole, pimonidazole and azomycin and intracellular uptake in human tumour cell lines. Int J Radiat Biol 57 (1990) 361-372
86. Dische S., Bennett M.H., Orchard R., Stratford M.R.L., and Wardman P. The uptake of the radiosensitizing compound Ro 03-8799 (pimonidazole) in human tumors. Int J Radiat Oncol Biol Phys 16 (1989) 1089-1092
87. Raleigh J.A., Dewhirst M.W., and Thrall D.E. Measuring tumor hypoxia. Semin Radiat Oncol 6 (1996) 37-45
88. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., Horsman M.R., and Group DHaNCS. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
89. Nagasawa H., Uto Y., Kirk K.L., and Hori H. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull 29 (2006) 2335-2342
90. Sugie C., Shibamoto Y., Ito M., et al. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res (Tokyo) 46 (2005) 453
91. Dobrowsky W., Huigol N.G., Jayatilake R.S., et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol 82 (2007) 24-29
92. 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg Med Chem 12 (2004) 6077-6084
93. Jonathan R.A., Wijffels K.I.E.M., Peeters W., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79 (2006) 288-297
94. Koch C.J., Evans S.M., and Lord E.M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: analysis of drug adducts by fluorescent antibodies vs. bound radioactivity. Br J Cancer 72 (1995) 869-874
95. Chapman J.D., Schneider R.F., Urbain J.L., and Hanks G.E. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol 11 (2001) 47-57
96. Sunamura M., Karasawa K., Okamoto A., et al. Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas 28 (2004) 330-334
97. von Sonntag C. The chemical basis of radiation biology (1987), Taylor & Francis, London
98. von Sonntag C. Free-radical-induced DNA damage and its repair. A chemical perspective (2006), Springer, Berlin
99. Wardman P. Sensitization and protection of oxidative damage caused by high energy radiation. In: Scott G. (Ed). Atmospheric oxidation and antioxidants Vol. III (1993), Elsevier, Amsterdam 101-127
100. Bamatraf M.M.M., O'Neill P., and Rao B.S.M. Redox dependence of the rate of interaction of hydroxyl radical adducts of DNA nucleobases with oxidants: consequences for DNA strand breakage. J Am Chem Soc 120 (1998) 11852-11857
101. Skov K.A. Workshop report. DNA targeted hypoxic cytotoxins and radiosensitizers. Int J Radiat Biol 56 (1989) 387-393
102. Cowan D.S.M., Matejovic J.F., McClelland R.A., and Rauth A.M. DNA-targeted 2-nitroimidazoles: in vitro and in vivo studies. Br J Cancer 70 (1994) 1067-1074
103. Cowan D.S.M., Matejovic J.F., Wardman P., McClelland R.A., and Rauth A.M. Radiosensitizing and cytotoxic properties of DNA-targeted phenanthridine-linked nitroheterocycles of varying electron affinities. Int J Radiat Biol 66 (1994) 729-738
104. Wilson W.R., Siim B.G., Denny W.A., et al. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine. Radiat Res 131 (1992) 257-265
105. Parrick J., Porssa M., Davies L.K., et al. Targeting radiosensitizers to DNA by minor groove binding: nitroarenes based on netropsin and distamycin. Bioorg Med Chem Lett 3 (1993) 1697-1702
106. Holley J., Mather A., Cullis P., et al. Uptake and cytotoxicity of novel nitroimidazole-polyamine conjugates in Ehrlich ascites tumour cells. Biochem Pharmacol 43 (1992) 763-769
107. Wardman P., Dennis M.F., and White J. A probe for intracellular concentrations of drugs: delayed fluorescence from acridine orange. Int J Radiat Oncol Biol Phys 16 (1989) 935-938
108. Stratford M.R.L., Dennis M.F., Watts M.E., Watfa R.R., and Woodcock M. Radiosensitizer-DNA interactions in relation to intracellular uptake. Int J Radiat Oncol Biol Phys 16 (1989) 1007-1010
109. Wilson W.R., and Hicks K.O. Measurement of extravascular drug diffusion in muticellular layers. Br J Cancer 79 (1999) 1620-1628
110. Kyle A.H., and Minchinton A.I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the mutilayered cell culture model. Cancer Chemother Pharmacol 43 (1999) 213-220
111. Hicks K.O., Pruijn F.B., Secomb T.W., et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 98 (2006) 1118-1128
112. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 6 (2006) 583-592
113. Brown J.M. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 319-326
114. Peters K.B., and Brown J.M. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62 (2002) 5248-5253
115. Foster J.L., Conroy P.J., Searle A.J., and Willson R.L. Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer 33 (1976) 485-490
116. Wardman P., and Clarke E.D. Oxygen inhibition of nitroreductase: electron transfer from nitro radical-anions to oxygen. Biochem Biophys Res Commun 69 (1976) 942-949
117. Laderoute K., Wardman P., and Rauth A.M. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzo-triazine-1,4-dioxide (SR 4233). Biochem Pharmacol 37 (1988) 1487-1495
118. Brown J.M., and Lemmon M.J. Potentiation of the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50 (1990) 7745-7749
119. Priyadarsini K.I., Tracy M., and Wardman P. The one-electron reduction potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine): a hypoxia-selective bioreductive drug. Free Radic Res 25 (1996) 393-399
120. Wardman P. Chemistry of nitroarene and aromatic N-oxide radicals. In: Alfassi Z.B. (Ed). The chemistry of N-centered radicals (1998), Wiley, New York 615-661
121. Zeman E.M., and Brown J.M. Pre- and post-irradiation radiosensitization by SR 4233. Int J Radiat Oncol Biol Phys 16 (1989) 967-971
122. Zeman E.M., Lemmon M.J., and Brown J.M. Aerobic radiosensitization by SR 4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys 18 (1990) 125-132
123. Itani W., Geara F., Haykal J., Haddadin M., and Gali-Muhtasib H. Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells. Radiat Oncol 2 (2007) 1-13
124. Jenkins T.C., Naylor M.A., O'Neill P., et al. Synthesis and evaluation of a-[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of a-[(1-aziridinyl)methyl]2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33 (1990) 2603-2610
125. Suto M.J., Stier M.A., Werbel L.M., et al. A new class of analogues of the bifunctional radiosensitizer a-(1-aziridinylmethyl)2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines. J Med Chem 34 (1991) 2484-2488
126. Bremner J.C.M. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev 12 (1993) 177-193
127. Wood P.J., Horsman M.R., Khalil A.A., et al. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour. Acta Oncol 35 (1996) 989-994
128. Lunt S.J., Telfer B.A., Fitzmaurice R.J., Stratford I.J., and Williams K.J. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res 11 (2005) 4212-4216
129. Ross AB, Mallard WG, Helman WP, Buxton GV, Huie RE, Neta P. NDRL-NIST Solution Kinetics Database: Version 3. Notre Dame, Indiana and Gaithersburg, Maryland: Notre Dame Radiation Laboratory and National Institute of Standards and Technology, 1998.
130. Shafirovich V., and Lymar S.V. Nitroxyl and its anion in aqueous solutions: spin states, protic equilibria, and reactivities toward oxygen and nitric oxide. Proc Natl Acad Sci USA 99 (2002) 7340-7345
131. Whitaker S.J., and McMillan T.J. Oxygen effect for DNA double-strand break induction determined by pulsed-field gel electrophoresis. Int J Radiat Biol 61 (1992) 29-41
132. Olive P.L., Bánath J.P., and MacPhail H.S. Lack of correlation between radiosensitivity and DNA double-strand breaks: induction or rejoining in six human tumor cell lines. Cancer Res 54 (1994) 3939-3946
133. Howard-Flanders P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 180 (1957) 1191-1192
134. Gray L.H., Green F.O., and Hawes C.A. Effect of nitric oxide on the radiosensitivity of tumour cells. Nature 182 (1958) 952-953
135. Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., and Krishna M.C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53 (1993) 5845-5848
136. Mitchell J.B., Cook J.A., Krishna M.C., et al. Radiation sensitization by nitric oxide releasing agents. Br J Cancer 74 Suppl. XXVII (1996) S181-S184
137. Mitchell J.B., DeGraff W., Kim S., et al. Redox generation of nitric oxide to radiosensitize hypoxic cells. Int J Radiat Oncol Biol Phys 42 (1998) 795-798
138. In: Ignarro L.J. (Ed). Nitric oxide. Biology and pathobiology (2000), Academic Press, San Diego
139. Worthington J., McCarthy H.O., Barrett E., Adams C., Robson T., and Hirst D.G. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 6 (2004) 673-680
140. Wang Z., Cook T., Alber S., et al. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 64 (2004) 1386-1395
141. Cook T., Wang Z., Alber S., et al. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 64 (2004) 8015-8021
142. Worthington J., Robson T., Scott S., and Hirst D. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Ther 12 (2005) 1417-1423
143. (WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 14 (2007) 246-255
144. Jordan B.F., Beghein N., Aubry M., Grégoire V., and Gallez B. Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSAII murine tumors. Int J Cancer 103 (2003) 138-141
145. Jordan B.F., Sonveaux P., Feron O., Grégoire V., Beghein N., and Gallez B. Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses. Int J Radiat Oncol Biol Phys 55 (2003) 1066-1073
146. Kashiwagi S., Izumi Y., Gohongi T., et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 115 (2005) 1816-1827
147. Shan S.Q., Rosner G.L., Braun R.D., Hahn J., Pearce C., and Dewhirst M.W. Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 76 (1997) 429-437
148. Sonveaux P., and Feron O. Nitric oxide and tumor biology. In: Lamas S., and Cadenas E. (Eds). Nitric oxide, cell signaling, and gene expression (2006), CRC Press, Boca Raton 395-420
149. Ichinose F., Roberts Jr. J.D., and Zapol W.M. Inhaled nitric oxide. A selective pulmonary vasodilator. Current uses and therapeutic potential. Circulation 109 (2004) 3106-3111
150. Hataishi R., Zapol W.M., Bloch K.D., and Ichinose F. Inhaled nitric oxide does not reduce systemic vascular resistance in mice. Am J Physiol Heart Circ Physiol 209 (2006) H1826-H1829
151. Ng Q.-S., Goh V., Milner J., et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8 (2007) 111-118
152. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
153. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 5 (2005) 423-435
154. Denekamp J. Limited role of vasculature-mediated injury in tumor response to radiotherapy. J Natl Cancer Inst 85 (1994) 935-937
155. Tozer G.M., and Everett S.A. Nitric oxide in tumour biology and cancer therapy. Part 2: therapeutic implications. Clin Oncol (R Coll Radiol) 9 (1997) 357-364
156. Tozer G.M., and Everett S.A. Nitric oxide in tumour biology and cancer therapy. Part 1: physiological aspects. Clin Oncol (R Coll Radiol) 9 (1997) 282-293
157. Jordan B.F., Grégoire V., Demeure R.J., et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 62 (2002) 3555-3561
158. De Ridder M., Verovski V.N., Chiavaroli C., et al. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys 66 (2006) 1473-1480
159. Behar D., and Neta P. Intramolecular electron transfer and dehalogenation of anion radicals. 2. Halonitroaromatic compounds. J Phys Chem 85 (1981) 690-693
160. Wilson W.R., Ferry D.M., Tercel M., Anderson R.F., and Denny W.A. Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechloramine by radiation. Radiat Res 149 (1998) 237-245
161. Kriste A.G., Tercel M., Anderson R.F., Ferry D.M., and Wilson W.R. Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine. Radiat Res 158 (2002) 753-762
162. Ahn G.-O., Ware D.C., Denny W.A., and Wilson W.R. Optimization of the auxiliary ligand shell of cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat Res 162 (2004) 315-325
163. Ahn G.-O., Botting K.J., Patterson A.V., Ware D.C., Tercel M., and Wilson W.R. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol 71 (2006) 1683-1694
164. Tanabe K., Makimura Y., Tachi Y., Imagawa-Sato A., and Nishimoto S. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics. Bioorg Med Chem Lett 15 (2005) 2321-2324
165. Shibamoto Y., Tachi T., Tanabe K., Hatta H., and Nishimoto S.-I. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2-deoxyuridine activated by hypoxic irradiation. Int J Radiat Oncol Biol Phys 58 (2004) 397-402
166. Cramp W.A. Radiosensitization by copper ions, and consequent reversal of the oxygen effect. Nature 206 (1965) 636-637
167. Hesslewood I.P., Cramp W.A., McBrien D.C.H., Williamson P., and Lott K.A.K. Copper as a hypoxic cell sensitizer of mammalian cells. Br J Cancer 37 Suppl. III (1978) 95-97
168. Selvaraj S, Chabita (Saha) K, Chakraborty A, Bhattacharyya SN, Saha A. Influence of copper (II) ions and its derivatives on radiosensitivity of Escherichia coli. Radiat Phys Chem (in press).
169. Buettner G.R., and Jurkiewicz B.A. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145 (1996) 532-541
170. Burkitt M.J. A critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydroperoxides, alpha-tocopherol, thiols, and ceruloplasmin. Arch Biochem Biophys 394 (2001) 117-135
171. Antholine W.E., Byrnes R., and Petering D.H. Copper complexes as drugs. In: Berthon G. (Ed). Handbook of metal-ligand interactions in biological fluids Vol. 2 (1995), Marcel Dekker, New York 1024-1038
172. Wardman P. The kinetics of the reaction of 'anomalous' 4-nitroimidazole radiosensitizers with thiols. Int J Radiat Biol 41 (1982) 231-235
173. Wardman P., and Clarke E.D. Redox properties and rate constants in free-radical mediated damage. Br J Cancer 55 Suppl. VIII (1987) 172-177
174. Young S.W., Qing F., Harriman A., et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 93 (1996) 6610-6615
175. Bernhard E.J., Mitchell J.B., Deen D., Cardell M., Rosenthal D.I., and Brown J.M. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res 60 (2000) 86-91
176. Sessler J.L., Tvermoes N.A., Guldi D.M., Mody T.D., and Allen W.E. One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(III) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. J Phys Chem A 103 (1999) 787-794
177. Magda D., Lepp C., Gerasimchuk N., et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51 (2001) 1025-1036
178. Wood P.M. The redox potential of the system oxygen-superoxide. FEBS Lett 44 (1974) 21-24
179. Wardman P. The reduction potential of benzyl viologen: an important reference compound for oxidant/radical redox couples. Free Radic Res Commun 14 (1991) 57-67
180. Renschler M.F. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 40 (2004) 1934-1940
181. Mikkelsen R.B., and Wardman P. Biological chemistry of reactive oxygen and nitrogen and ionizing radiation-induced signal transduction mechanisms. Oncogene 22 (2003) 5734-5754
182. Rockwell S., Donnelly E.T., Liu Y., and Tang L.Q. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys 54 (2002) 536-541
183. Donnelly E.T., Liu Y., Paul T.K., and Rockwell S. Effects of motexafin gadolinium on DNA damage and X-ray-induced DNA damage repair, as assessed by the Comet assay. Int J Radiat Oncol Biol Phys 62 (2004) 1176-1186
184. Xu S., Zakian K., Thaler H., et al. Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 49 (2001) 1381
185. Donnelly E.T., Liu Y., Fatunmbi Y.O., Lee I., Magda D., and Rockwell S. Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 58 (2004) 1570-1576
186. Magda D., and Miller R.A. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 16 (2006) 466-476
187. Khuntia D., and Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4 (2004) 981-989
188. Richards G.M., and Mehta M.P. Motexafin gadolinium in the treatment of brain metastases. Expert Opin Pharmacother 8 (2007) 351-359
189. Gomer C.J., Rucker N., Ferrario A., and Wong S. Properties and applications of photodynamic therapy. Radiat Res 120 (1989) 1-18
190. Schaffer M., Schaffer P.M., Hofstetter A., Dühmke E., and Jori G. On the double role of Photofrin as a photo- and a radio-sensitising agent: a possible new combination therapy for tumours. Photochem Photobiol 1 (2002) 438-439
191. Schaffer M., Ertl-Wagner B., Schaffer P.M., et al. The application of Photofrin II as a sensitizing agent for ionizing radiation - a new approach in tumor therapy?. Curr Med Chem 12 (2005) 1209-1215
192. Schaffer M., Ertl-Wagner B., Schaffer P.M., et al. Feasibility of photofrin II as a radiosensitizing agent in solid tumors - preliminary results. Onkologie 29 (2006) 514-519
193. Kinsella T.J., Dobson P.P., Mitchell J.B., and Fornace Jr. A.J. Enhancement of X-ray induced DNA damage by prep-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13 (1987) 1-7
194. Seo Y., Yan T., Schupp J.E., Colussi V., Taylor K.L., and Kinsella T.J. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2-deoxyribose. Clin Cancer Res 10 (2004) 7520-7528
195. Berry S.E., and Kinsella T.J. Targeting DNA mismatch repair for radiosensitization. Semin Radiat Oncol 11 (2001) 300-315
196. McGinn C.J., Shewach D.S., and Lawrence T.S. Radiosensitizing nucleosides. J Natl Cancer Inst 88 (1996) 1193-1203
197. McGinn C.J., and Lawrence T.S. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11 (2001) 270-280
198. Glynne-Jones R., and Debus J. Improving chemoradiotherapy in rectal cancer. Oncologist 6 Suppl. 4 (2001) 29-34
199. Zhu A.X., and Willett C.G. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol 13 (2003) 454-468
200. Vallerga A.K., Zarling D.A., and Kinsella T.J. New radiosensitizing regimens, drugs, prodrugs, and candidates. Clin Adv Hematol Oncol 2 (2004) 793-805
201. Pauwels B., Korst A.E.C., Lardon F., and Vermorken J.B. Combined modality therapy of gemcitabine and radiation. Oncologist 10 (2005) 34-51
202. Douple E.B., Richmond R.C., O'Hara J.A., and Coughlin C.T. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12 Suppl. A (1985) 111-124
203. Yang L., Douple E.B., O'Hara J.A., Crabtree R.A., and Eastman A. Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines. Radiat Res 144 (1995) 230-236
204. Yang L.X., Douple E.B., O'Hara J.A., and Wang H.J. Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 143 (1995) 309-315
205. 3)(Sensitizer)]: radiosensitization and toxicity studies in vitro. Radiat Res 112 (1987) 273-282
206. Skov K.A. Modification of radiation response by metal complexes: a review with emphasis on nonplatinum studies. Radiat Res 112 (1987) 217-242
207. Chan P.K.L., Skov K.A., and James B.R. Further studies on toxic and radiosensitizing properties of ruthenium complexes of 4-nitroimidazoles. Int J Radiat Biol 52 (1987) 49-55
208. Eberhardt W., Pöttgen C., and Stuschke M. Chemoradiation paradigm for the treatment of lung cancer. Nat Clin Pract Oncol 3 (2006) 188-199
209. Hao D., Ritter M.A., Oliver T., and Browman G.P. Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin Radiat Oncol 18 (2006) 10-19
210. Miyamoto S., Huang T.T., Würzberger-Davis S., et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N Y Acad Sci 922 (2000) 274-292
211. Chen A.Y., Chou R., Shih S.-J., Laub D., and Gandara D. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol 50 (2004) 111-119
212. Shih S.J., Erbele T., and Chen A.Y. Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells. Cancer Res 65 (2005) 9194-9199
213. Wong E.T., and Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 9 (2004) 68-79
214. Patterson L.H., McKeown S.R., Ruparelia K., et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82 (2000) 1984-1990
215. McErlane V., Yakkundi A., McCarthy H.O., et al. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J Gene Med 7 (2005) 851-859
216. Zhang M., and Chakravarti A. Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol 16 (2006) 29-37
217. Virág L., and Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54 (2002) 375-429
218. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 (2004) 56-67
219. Sarkaria J.N., and Eshleman J.S. ATM as a target for novel radiosensitizers. Semin Radiat Oncol 11 (2001) 316-327
220. Wong J.S., Ara G., Keyes S.R., Herbst R., Coleman C.N., and Teicher B.A. Lisofylline as a modifier of radiation therapy. Oncol Res 8 (1996) 513-518
221. Choudhury A., Cuddihy A., and Bristow R.G. Radiation and new molecular agents. Part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 16 (2006) 51-58
222. Chinnaiyan P., Allen G.W., and Harari P.M. Radiation and new molecular agents. Part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 16 (2006) 59-64
223. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003) 11-22
224. Gupta A.K., Bakanauskas V.J., Cerniglia G.J., et al. The Ras radiation resistance pathway. Cancer Res 61 (2001) 4278-4282
225. Cengel K.A., and McKenna W.G. Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model. Crit Rev Oncol Hematol 55 (2005) 103-116
226. Sartor C.I. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 1 (2004) 80-87
227. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
228. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
229. Posner M.R., and Wirth L.J. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 354 (2006) 634-636
230. Harari P.M., and Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol 16 (2006) 38-44
231. Liao Z., Komaki R., Milas L., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 (2005) 3342-3348
232. Raju U., Ariga H., Dittmann K., Nakata E., Ang K.K., and Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 63 (2005) 520-528
233. Nieder C., Wiedenmann N., Andratschke N., and Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32 (2006) 348-364
234. Miura M., Sakimoto I., Ohta K., Sugawara F., and Sakaguchi K. Sulfoglycolipids as candidate antiangiogenic radiosensitizers. Anti-Cancer Drugs 18 (2007) 1-5
235. Jendrossek V., and Handrick R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitizers. Curr Med Chem Anti-Cancer Agents 3 (2003) 343-353
236. Bridges B.A. Sensitization of Escherichia coli to gamma-radiation by N-ethylmaleimide. Nature 4748 (1960) 415
237. Bridges B.A. Sensitization of organisms to radiation by sulfhydryl-binding agents. Adv Radiat Biol 3 (1969) 123-176
238. Watts M.E., Whillans D.W., and Adams G.E. Studies of the mechanisms of radiosensitization of bacterial and mammalian cells by diamide. Int J Radiat Biol 27 (1975) 259-270
239. Harris J.W. Mammalian cell studies with diamide. Pharmacol Ther 7 (1979) 375-391
240. Wardman P. Thiol reactivity towards drugs and radicals: some implications in the radiotherapy and chemotherapy of cancer. In: Chatgilialoglu C., and Asmus K.-D. (Eds). Sulfur-centered reactive intermediates in chemistry and biology (1990), Plenum Press, New York 415-427
241. Griffith O.W., and Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254 (1979) 7558-7560
242. Hodgkiss R.J., and Middleton R.W. Enhancement of misonidazole radiosensitization by an inhibitor of glutathione biosynthesis. Int J Radiat Biol 43 (1983) 179-183
243. Minchinton A.I., Rojas A., Smith K.A., et al. Glutathione depletion in tissues after administration of buthionine sulphoximine. Int J Radiat Oncol Biol Phys 10 (1984) 1261-1264
244. Rojas A., Smith K.A., Soranson J.A., Minchinton A.I., Middleton R.W., and Denekamp J. Enhancement of misonidazole radiosensitization by buthionine sulphoximine. Radiother Oncol 2 (1984) 325-332
245. Lespinasse F., Biscay P., Malaise E.P., and Guichard M. SR-2508 plus buthionine sulfoximine or SR-2508 alone: effect on the radiation response and the glutathione content of a human tumor xenograft. Radiat Res 110 (1987) 149-154
246. Ono K., Komuro C., Nishidai T., et al. Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors. Int J Radiat Oncol Biol Phys 12 (1986) 1661-1666
247. Minchinton A.I., and Chaplin D.J. Spatial characterization of glutathione depletion in the KHT sarcoma using flow cytometry. Int J Radiat Biol 59 (1991) 1425-1433
248. Vukovic V., Nicklee T., and Hedley D.W. Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res 6 (2000) 1826-1832
249. Vukovic V., Nicklee T., and Hedley D.W. Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiother Oncol 60 (2001) 69-73
250. Bailey H.H., Ripple G., Tutsch K.D., et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 89 (1997) 1789-1796
251. Bailey H.H. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 111-112 (1998) 239-254
252. Hamilton D., Wu J., and Batist G. Structure-based identification of novel classes of human γ-glutamylcysteine synthetase inhibitors. Mol Pharmacol 71 (2007) 1140-1147
253. Koch C.J., and Evans S.M. Cysteine concentrations in rodent tumors: unexpectedly high values may cause therapy resistance. Br J Cancer 67 (1996) 661-667
254. Kinnaert E., Duez P., Morandini R., Dubois J., Van Houtte P., and Ghanem G. Cysteine but not glutathione modulates the radiosensitivity of human melanoma cells by affecting both survival and DNA damage. Pigment Cell Res 17 (2004) 275-280
255. Biaglow J.E., Ayene I.S., Koch C.J., et al. Radiation response of cells during altered protein thiol redox. Radiat Res 159 (2003) 484-494
256. O'Neill P. Pulse radiolytic study of the interaction of thiols and ascorbate with OH adducts of dGMP and dG: implications for DNA repair processes. Radiat Res 96 (1983) 198-210
257. Hodgkiss R.J., and Stratford M.R.L. Competitive dose-modification between ascorbate and misonidazole in human and hamster cells: effects of glutathione depletion. Int J Radiat Biol 54 (1988) 601-610
258. Coleman C.N., and Mitchell J.B. Clinical radiosensitization: why it does and does not work. J Clin Oncol 17 (1999) 1-3
259. Hornig D. Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann NY Acad Sci 258 (1975) 103-117
260. Wardman P. Evaluation of the 'radical sink' hypothesis from a chemical-kinetic viewpoint. J Radioanal Nucl Chem 232 (1998) 23-27